LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Equitable Access to High-Cost Pharmaceuticals
- 1st Edition - February 21, 2018
- Editor: Zaheer-Ud-Din Babar
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 1 9 4 5 - 7
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 1 9 6 2 - 4
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health ec… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteEquitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.
- Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
- Incorporates existing guidelines and recommendations by international organizations
- Compares and contrasts how different countries fund and police high-cost drug access
- Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
- Reviews novel pharmaceuticals of current research interest
Pharmacoeconomics, health economics, pharmacy, public health and health administration professionals. Policymakers and funding bodies. Pharmaceutical research and insurance staff working across pricing, market access, policy and marketing. Some graduate and 1st year PhD students studying pharmacoeconomics, pharmacy and health economics
1. Access to High Cost Medicines: An Overview
2. Health Technology Assessment
3. High-Cost Medicines in England
4. Managed Entry Agreements and High Cost Medicines (European Perspective)
5. Setting a Public Health Agenda to Support Access to High-Cost Medicines
6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines
7. Access to High Price Medicines in Portugal
8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda
9. Equitable Access to Biosimilars: An Overview
10. Access to High-Cost Medicines in Europe
11. Access to High-Cost Medicines in Australia
12. Access to High-Cost Medicines in New Zealand
13. Access to High-Cost Medicines in Wales
- No. of pages: 238
- Language: English
- Edition: 1
- Published: February 21, 2018
- Imprint: Academic Press
- Paperback ISBN: 9780128119457
- eBook ISBN: 9780128119624
ZB
Zaheer-Ud-Din Babar
With over 25 years of experience in pharmaceutical policy and practice research, Prof Zaheer Babar is a global authority and a prolific author in this field. He comes with a long-standing academic career in pharmacy in New Zealand, and the United Kingdom. He is globally known for his work in policy and practice, including quality use of medicines, and issues related to medicines access and pricing.
Prof. Babar has published over 300 papers and is considered the leading researcher in the “pharmacy practice research category”. He has published in high-impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for the WHO, RPS, UNDP, HAI, MSH, FIP, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, and the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic Evaluation of Pharmacy Services", "Pharmaceutical Prices in the 21st Century", "Pharmaceutical Policies in Countries with Developing Healthcare Systems", "Global Pharmaceutical Policy", "Access to high-cost medicines", "Pharmacy Practice Research Methods", "Pharmacy Practice Research Case Studies" , "Encyclopaedia of Pharmacy Practice and Clinical Pharmacy", and "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy". Published by Elsevier and Adis/Springer, his work is used in curriculum design, policy development, and referral all around the globe. Professor Babar is the founding Editor-In-Chief of the Journal of Pharmaceutical Policy and Practice [IF = 4.2], a high-impact publication that provides evidence-based insights and recommendations for policymakers, practitioners, and researchers. He can be contacted at: [email protected]
Affiliations and expertise
Professor of Clinical Pharmacy and Practice College of Pharmacy, Qatar University, QatarRead Equitable Access to High-Cost Pharmaceuticals on ScienceDirect